Acumen Pharmaceuticals, (id:8281 ABOS)
2.37 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 6:40:23 PM)
Exchange closed, opens in 14 hours 49 minutes
3.04 USD (3.04%)
-0.42 USD (-0.42%)
-1.25 USD (-1.25%)
-31.30 USD (-31.30%)
0.85 USD (0.85%)
-90.88 USD (-90.88%)
About Acumen Pharmaceuticals,
Market Capitalization 142.39M
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
| Headquarters (address) |
427 Park Street Charlottesville 22902 VA United States |
| Phone | 434 297 1000 |
| Website | https://acumenpharm.com |
| Employees | 51 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ABOS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.08 - 5.09 |
| Market Capitalization | 142.39M |
| P/E trailing | -2.19 |
| P/E forward | -1.55 |
| Price/Book | 0.656 |
| Beta | 0.039 |
| EPS | -1.38 |
| EPS United States (ID:6, base:3402) | 24.22 |